Steve Thorne co-founded Western Oncolytics in 2014 and currently serves as Chief Scientific Officer and acting CEO. He is a leader in the field of oncolytic viral immunotherapy and previously founded Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials. Steve was previously a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London. Steve has served in postdoctorate roles at Surrey University, Cancer Research UK, and Stanford University and has authored more than 65 scientific publications in the field